David Einhorn
Greenlight Capital
David Einhorn Lakefront Biotherapeutics NV stake
total: 357
Greenlight Capital LKFT trades
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 6
- Reduced:
- 5
- Held since:
- 2021 Q4
- Held for:
- 19 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q2 report, David Einhorn holds 482,746 Lakefront Biotherapeutics NV (LKFT) shares with a market value of roughly $14.47M accounting for 0.37% of the overall portfolio. To date, the estimated cost basis is nearly $37.88 for "buy" trades and estimated average "sell" price is $55.86. Greenlight Capital first purchased LKFT in 2021 Q4, initially acquiring 185,000 shares. Since the initial investment in Lakefront Biotherapeutics NV (LKFT), Greenlight Capital has made 11 more transactions.
When did David Einhorn buy Lakefront Biotherapeutics NV (LKFT)?
David Einhorn first invested in Lakefront Biotherapeutics NV (LKFT) in 2021 Q4 at the reported quarter-end price of $55.13 per share.
What's the cost basis of Greenlight Capital's LKFT stake?
The estimated cost basis for Lakefront Biotherapeutics NV (LKFT) stake is around $37.88 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $37.88
- Weighted AVG sell price:
- $55.86
David Einhorn's historical trades in Lakefront Biotherapeutics NV
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.61%
|
482,746
|
$25.12
|
$12,126,580
|
+0.71% (+3,383)
|
+0%
|
|
2024 Q3
|
0.57%
|
479,363
|
$28.79
|
$13,800,860
|
+104.13% (+244,535)
|
+0.29%
|
|
2024 Q2
|
0.28%
|
234,828
|
$24.78
|
$5,819,038
|
+46.93% (+75,000)
|
+0.09%
|
|
2024 Q1
|
0.24%
|
159,828
|
$32.20
|
$5,146,462
|
-1.69% (-2,750)
|
-0%
|
|
2023 Q4
|
0.32%
|
162,578
|
$40.65
|
$6,608,796
|
+3.96% (+6,200)
|
+0.01%
|
|
2023 Q3
|
0.31%
|
156,378
|
$34.55
|
$5,402,861
|
+4.14% (+6,210)
|
+0.01%
|
|
2023 Q2
|
0.29%
|
150,168
|
$40.66
|
$6,105,832
|
-0.79% (-1,200)
|
-0%
|
|
2023 Q1
|
0.32%
|
151,368
|
$38.64
|
$5,848,859
|
-2.57% (-3,990)
|
-0.01%
|
|
2022 Q4
|
0.48%
|
155,358
|
$44.38
|
$6,894,789
|
+6.13% (+8,970)
|
+0.03%
|
|
2022 Q2
|
0.64%
|
146,388
|
$55.80
|
$8,169,000
|
-8.62% (-13,812)
|
-0.05%
|
|
2022 Q1
|
0.63%
|
$62.02
|
-13.41% (-24,800)
|
|||
|
2021 Q4
|
0.62%
|
$55.13
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.